After Carbylan’s scrapped $93M IPO, it’s raising $4M in debt
In the wake of postponing its IPO, SEC filings show Carbylan Therapeutics just raised $4 million in debt. The Palo Alto pharma was founded in 2004 is developing an injection that can treat joint pain associated with osteoarthritis. It chemically engineers biopolymers with hyaluronic acid as a localized drug delivery system. Late last year Carbylan filed a $93 […]